{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:23:41Z","timestamp":1790630621665,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Organ transplants have been a life-saving form of treatment for many patients who are facing end stage organ failure due to conditions such as diabetes, hypertension, various congenital diseases, idiopathic diseases, traumas, and other end-organ failure. While organ transplants have been monumental in treatment for these conditions, the ten year survival and long-term outcome for these patients is poor. After receiving the transplant, patients receive a multi-drug regimen of immunosuppressants. These drugs include cyclosporine, mTOR inhibitors, corticosteroids, and antibodies. Polyclonal antibodies, which inhibit the recipient\u2019s B lymphocytes, and antibodies targeting host cytokine inhibitors which prevent activation of B cells by T cells. Use of these drugs suppresses the immune system and increases the risk of opportunistic pathogen infections, tumors, and further damage to the transplanted organs and vasculature. Many regulatory mechanisms are present in organs to prevent the development of autoimmune disease, and Tregs are central to these mechanisms. Tregs secrete suppressive cytokines such as IL-10, TGF-B, and IL-35 to suppress T cells. Additionally, Tregs can bind to target cells to induce cell cycle arrest and apoptosis and can inhibit induction of IL-2 mRNA in target T cells. Tregs also interact with CTLA-4 and CD80\/CD86 on antigen presenting cells (APCs) to prevent their binding to CD28 present on T cells. Due to their various immunosuppressive capabilities, Tregs are being examined as a possible treatment for patients that receive organ transplants to minimize rejection and prevent the negative outcomes. Several studies in which participants were given Tregs after undergoing organ transplantations were reviewed to determine the efficacy and safety of using Tregs in solid organ transplantation to prevent adverse outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2022.746889","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T05:15:31Z","timestamp":1643951731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Utilization of Treg Cells in Solid Organ Transplantation"],"prefix":"10.3389","volume":"13","author":[{"given":"Tanya","family":"Juneja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mellace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza F.","family":"Saidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00354","article-title":"Cell Therapy in Organ Transplantation: Our Experience on the Clinical Translation of Regulatory T Cells","volume":"9","author":"Safinia","year":"2018","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The Biology of Chronic Graft-Versus-Host Disease: A Task Force Report From the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B3","volume-title":"Risk Factors: Immunosuppression [Internet]","year":"2015"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05597-y","article-title":"Diagnostic and Therapeutic Approach to Infectious Diseases in Solid Organ Transplant Recipients","volume":"45","author":"Timsit","year":"2019","journal-title":"Intensive Care Med"},{"key":"B5","unstructured":""},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.03.002","article-title":"Development and Maintenance of Regulatory T Cells","volume":"38","author":"Ohkura","year":"2013","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.001","article-title":"The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases","volume":"49","author":"Roncarolo","year":"2018","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12445","article-title":"Infiltrating Foxp3(+) Regulatory T Cells From Spontaneously Tolerant Kidney Allografts Demonstrate Donor-Specific Tolerance","volume":"13","author":"Hu","year":"2013","journal-title":"Am J Transpl"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trim.2016.04.005","article-title":"Utility of CD127 Combined With FOXP3 for Identification of Operational Tolerance After Liver Transplantation","volume":"36","author":"Ohe","year":"2016","journal-title":"Transpl Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/01.tp.0000203166.44968.86","article-title":"Contrasting Cd25hicd4+T Cells\/FOXP3 Patterns in Chronic Rejection and Operational Drug-Free Tolerance","volume":"81","author":"Louis","year":"2006","journal-title":"Transplantation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15700","article-title":"Applicability, Safety, and Biological Activity of Regulatory T Cell Therapy in Liver Transplantation","volume":"20","author":"S\u00e1nchez-Fueyo","year":"2020","journal-title":"Am J Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28459","article-title":"A Pilot Study of Operational Tolerance With a Regulatory T-Cell-Based Cell Therapy in Living Donor Liver Transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25574-7","article-title":"A Phase I Clinical Trial With Ex Vivo Expanded Recipient Regulatory T Cells in Living Donor Kidney Transplants","volume":"8","author":"Mathew","year":"2018","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14415","article-title":"Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants","volume":"17","author":"Chandran","year":"2017","journal-title":"Am J Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16395","article-title":"Feasibility, Long-Term Safety and Immune Monitoring of Regulatory T Cell Therapy in Living Donor Kidney Transplant Recipients","volume":"21","author":"Harden","year":"2020","journal-title":"Am J Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3734","article-title":"Regulatory T Cells for Minimising Immune Suppression in Kidney Transplantation: Phase I\/IIa Clinical Trial","volume":"371","author":"Roemhild","year":"2020","journal-title":"BMJ (Clin Res Ed)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003149","article-title":"A Clinical Trial With Adoptive Transfer of Ex Vivo-Induced, Donor-Specific Immune-Regulatory Cells in Kidney Transplantation\u2014A Second Report","volume":"104","author":"Koyama","year":"2020","journal-title":"Transplantation"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.40796","article-title":"Adenosine 2a Receptor Signal Blockade of Murine Autoimmune Arthritis via Inhibition of Pathogenic Germinal Center-Follicular Helper T Cells","volume":"71","author":"Schmiel","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jneuroim.2017.08.002","article-title":"Adenosine A2A Receptor Signaling Affects IL-21\/IL-22 Cytokines and GATA3\/T-Bet Transcription Factor Expression in CD4+ T Cells From a BTBR T+ Itpr3tf\/J Mouse Model of Autism","volume":"311","author":"Ahmad","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00379","article-title":"The Molecular Mechanisms of Regulatory T Cell Immunosuppression","volume":"3","author":"Smith","year":"2012","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","article-title":"Molecular and Cellular Functions of CTLA-4","volume":"1248","author":"Van Coillie","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2017.12.010","article-title":"Anti-Donor Regulatory T Cell Therapy in Liver Transplantation","volume":"79","author":"Todo","year":"2018","journal-title":"Hum Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory Cell Therapy in Kidney Transplantation (The ONE Study): A Harmonised Design and Analysis of Seven Non-Randomised, Single-Arm, Phase 1\/2A Trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"B24","volume-title":"Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection [Internet]","author":"Bykovskaia","year":"2011"},{"key":"B25","volume-title":"Liver Transplantation With Tregs at MGH - Full Text View - ClinicalTrials.Gov [Internet]","author":"Markmann","year":"2019"},{"key":"B26","volume-title":"A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients [Internet]","author":"Gedaly","year":"2019"},{"key":"B27","volume-title":"The ONE Study Ntreg Trial (ONEnTreg13) - Full Text View - ClinicalTrials.Gov [Internet]","author":"Reinke","year":"2020"},{"key":"B28","volume-title":"Donor Alloantigen Reactive Tregs (Dartregs) for Calcineurin Inhibitor (CNI) Reduction - Full Text View - ClinicalTrials.gov [Internet]","author":"Feng","year":"2021"},{"key":"B29","volume-title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation - Full Text View - ClinicalTrials.Gov [Internet]","author":"Vincenti","year":"2021"},{"key":"B30","volume-title":"The ONE Study UK Treg Trial - Full Text View - ClinicalTrials.Gov [Internet]","author":"Lombardi","year":"2019"},{"key":"B31","unstructured":"Ukri.org"},{"key":"B32","volume-title":"Infusion of Tregulatory Cells in Kidney Transplant Recipients (The ONE Study) [Internet]","author":"Markmann","year":"2021"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20872","article-title":"Early Immunosuppression Withdrawal After Living Donor Liver Transplantation and Donor Stem Cell Infusion","volume":"12","author":"Donckier","year":"2006","journal-title":"Liver Transpl"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2004.05.004","article-title":"Donor Stem Cell Infusion After Non-Myeloablative Conditioning for Tolerance Induction to HLA Mismatched Adult Living-Donor Liver Graft","volume":"13","author":"Donckier","year":"2004","journal-title":"Transpl Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181b164d5","article-title":"Full Donor Chimerism Using Stem-Cell Transplantation for Tolerance Induction in the Human Leukocyte Antigen-Matched Liver Transplant Setting","volume":"88","author":"Kim","year":"2009","journal-title":"Transplantation"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.03992.x","article-title":"Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants","volume":"12","author":"Scandling","year":"2012","journal-title":"Am J Transplant"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12731","article-title":"Long-Term Results in Recipients of Combined HLA-Mismatched Kidney and Bone Marrow Transplantation Without Maintenance Immunosuppression","volume":"14","author":"Kawai","year":"2014","journal-title":"Am J Transpl"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.746889\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T05:15:44Z","timestamp":1643951744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.746889\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2022.746889"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.746889","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"article-number":"746889"}}